Sequential Administration of Interferon-γ, GM-CSF, and Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: Results of a Phase II Trial-Reference-Cited by-同舟云学术

Sequential Administration of Interferon-γ, GM-CSF, and Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: Results of a Phase II Trial

Published:2001-05 Issue:3 Volume:24 Page:257-262
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:Journal of Immunotherapy

Author:

Schmidinger Manuela,Steger Guenther,Wenzel Catharina,Locker Gottfried J.,Budinsky Alexandra C.,Brodowicz Thomas,Kramer Gero,Marberger Michael,Zielinski Christoph C.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference35 articles.

1. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.

2. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer the national biotherapy study group experience

3. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

4. Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

5. Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?;Drugs;2022-02-17

2. Creation of lysine-deficient mutant lymphotoxin-α with receptor selectivity by using a phage display system;Biomaterials;2010-03

3. Granulocyte Macrophage-Colony Stimulating Factor Plus Interleukin-2 Plus α-interferon Plus 5-Fluorouracil in the Treatment of Metastatic Renal Cell Cancer;Journal of Immunotherapy;2009-07

4. Economic evaluation of temsirolimus on the basis of the results of the ARCC (Advanced Renal-Cell Carcinoma) study;Farmeconomia. Health economics and therapeutic pathways;2009-06-15

5. The burden of renal cell cancer: A retrospective longitudinal study on occurrence, outcomes and cost using an administrative claims database;European Journal of Cancer Supplements;2008-10